0001567619-19-019202.txt : 20191003 0001567619-19-019202.hdr.sgml : 20191003 20191003151425 ACCESSION NUMBER: 0001567619-19-019202 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191003 DATE AS OF CHANGE: 20191003 EFFECTIVENESS DATE: 20191003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HDL THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001569047 IRS NUMBER: 273015978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-350299 FILM NUMBER: 191135365 BUSINESS ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 BUSINESS PHONE: 772-453-2770 MAIL ADDRESS: STREET 1: 601 21ST STREET STREET 2: SUITE 300 CITY: VERO BEACH STATE: FL ZIP: 32960 D 1 primary_doc.xml X0708 D LIVE 0001569047 HDL THERAPEUTICS, INC. 601 21st Street Suite 300 Vero Beach FL FLORIDA 32960 772-453-2770 DELAWARE None None Corporation true Michael Matin c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Mr. Matin is the Chief Executive Officer and Secretary of the Issuer. Bryan Brewer c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Executive Officer Director Dr. Brewer is the Chief Scientific Officer of the Issuer. Dane Andreeff c/o HDL Therapeutics, Inc. 601 21st Street, Suite 300 Vero Beach FL FLORIDA 32960 Director Biotechnology Decline to Disclose 06b false 2019-09-19 false true true Series D Preferred Stock false 0 3000070 3000019 51 false 34 0 0 0 false HDL THERAPEUTICS, INC. /s/ Michael Matin Michael Matin Chief Executive Officer of the Issuer 2019-10-03